Does Marijuana Rescheduling in the U.S. Make Canopy Growth a Good Buy in 2026?

President Trump signed an executive order rescheduling marijuana from Schedule I to Schedule III, which should ease research and relieve U.S. multi-state operators of section 280E tax restrictions; however, Canada-based Canopy Growth (market cap ≈ $500M) is unlikely to materially benefit. Canopy reported an operating loss of CA$16.9M (≈US$12.2M) for the quarter ended Sept. 30 versus CA$45.9M a year earlier, six-month cash burn of CA$28.3M (vs CA$105.6M prior year) and quarterly revenue of ~CA$83M (down ~30% from ~CA$118M three years ago), leaving the business shrinking and the stock highly risky despite any industry-level optimism.

Analysis

Market structure: Rescheduling to Schedule III principally benefits U.S. multi-state operators (MSOs) and ancillary service providers by easing research and, if IRS/legislation follows, removing 280E tax drag (potentially improving net margins by ~15–25% for profitable MSOs). Canadian LPs (CGC) remain sidelined because federal rescheduling does not grant cross-border market access or state licenses, so competitive power shifts to well-capitalized U.S. MSOs and consolidators. Oversupply in Canadian production persists and will keep downward pressure on wholesale prices, maintaining margin compression for Canadian growers.

Risk assessment: Immediate (days) risk is a sentiment pop; short-term (30–90 days) hinge on DEA/IRS/FinCEN guidance — lack of clear IRS 280E relief is a critical tail risk that would reverse gains. Medium-term (6–18 months) bankruptcy and dilution risk remains for weak balance sheets (CGC style) if revenue doesn’t stabilize; long-term (2–5 years) outcomes depend on Congress or federal rulemaking for banking and interstate commerce. Hidden dependencies include state licensing, access to banking/payment rails, and M&A financing availability.

Trade implications: Favor selective longs in U.S. MSOs and ancillary plays ahead of confirmed IRS guidance, size 1–3% positions, target 30–50% upside over 12–24 months; short structurally weak Canadian LPs (CGC) via limited-duration options to cap risk. Use pair trades (long MSO, short CGC) to express regulatory-discrimination thesis; employ 3–6 month call spreads for MSOs around key rulings and 6–9 month put spreads to short CGC. Rotate out of Canadian cannabis ETFs into U.S. ancillary/payments/banking names if banking reform signals appear.

Contrarian angle: Markets conflate rescheduling with immediate legalization — consensus underestimates state-level frictions and the time to translate tax relief into cash flow. CGC’s 99% drawdown prices in severe outcomes, making deep-value turnaround possible but unlikely without structural change; therefore downside asymmetry remains. Historical parallels (alcohol/recreational regulation shifts) show winners are consolidators and service providers, not commodity growers; expect M&A interest in underpriced U.S. MSOs within 12–36 months, creating idiosyncratic takeover opportunities.

Key Decisions for Investors

• Establish a bearish options position on Canopy Growth (CGC): buy a 6–9 month at-the-money put and sell a 30% OTM put to halve premium (size 1–2% portfolio). Target 40–60% payoff if CGC falls; close if quarterly revenue growth turns positive y/y >10% or management announces >15% shrinkage in share count or successful U.S. transaction.
• Initiate a pair trade: long a well-capitalized U.S. MSO (example tickers: CURLF or GTBIF) sized 1–3% and short an equal-dollar position in CGC. Enter after DEA/IRS comment period (30–90 days); set profit target +30–50% on long within 12–24 months and stop-loss at -25% on either leg.
• Buy 3–6 month call spreads on a U.S. cannabis ancillary/banking beneficiary (consider NDAQ call spread for listing/banking flow exposure) sized 0.5–1% to capture upside from banking/listing reforms. Close on +20% return or after 6 months if no supportive regulatory action.
• Reduce/avoid Canadian cannabis equity exposure: trim Canadian LP holdings (CGC included) to <0.5% of risk-weighted portfolio until concrete IRS/legislative guidance appears (monitor IRS 280E ruling within 90 days and Congressional action within 12 months).